Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others) - Forecast till 2023
Duloxetine Active Pharmaceutical Ingredients (API) Market Analysis
The global duloxetine API market is likely to touch USD 3,985.0 million at a 3.52% CAGR between 2017- 2023, reveals the new Market Research Future (MRFR) report. Active pharmaceutical ingredients or API are utilized to manufacture pharmaceutical formulations. Duloxetine is an effective serotonin-norepinephrine reuptake inhibitor that is used to treat anxiety and depression. Besides, it is also used to relieve neuropathic pain in those with ongoing pain due to medical conditions like fibromyalgia, chronic back pain, or arthritis, or those suffering from diabetes
Get Free Sample Copy @https://www.marketresearchfuture.com/sample_request/7707
Duloxetine blocks the reabsorption of serotonin and neurotransmitters norepinephrine in the brain. Serotonin is a naturally occurring neurotransmitter that plays an imperative role in various bodily functions such as pain perception, gastrointestinal function, and mood regulation. Noradrenaline or norepinephrine is both a neurotransmitter and a hormone. This chiefly acts in the locus coeruleus, which is a part of the brainstem. It impacts how people perceive the thought process, blood pressure, movement, emotions, mood, and pain. Duloxetine helps to boost the amount of norepinephrine and serotonin in the brain. Such chemicals stop the movement of the pain signals in the brain and keep mental balance. Chronic musculoskeletal pain, neuropathic pain, fibromyalgia, generalized anxiety disorder, major depressive disorder, and others are some of its key applications.
Various factors are adding to the duloxetine API market share. Such factors, as revealed by the latest MRFR report, include the increasing trend of outsourcing, rising prevalence of anxiety, rising penetration of generic drugs, and increasing cases of depression. Besides, the burgeoning demand for newly made small molecule drugs is also adding market growth.
Duloxetine Active Pharmaceutical Ingredients (API) Market Segment analysis
The global Duloxetine Active Pharmaceutical Ingredients (API) Market has been segmented into application. Based on application, the market has been segmented into major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain, chronic musculoskeletal pain, and others. The chronic musculoskeletal pain accounted for a market value of USD 200.0 million in 2017.
Regional Analysis
Geographically, the Americas is expected to dominate the global duloxetine API market. In this region, North America is expected to dominate the market owing to the increasing incidence of chronic diseases such as psychological disorders, diabetes, increasing government focus on generic drugs, and technological advancements in the manufacturing processes of APIs. In Europe, the market growth is majorly due to the increasing pharmaceutical sector. Additionally, in Europe, countries such as the UK, Germany, and France have a higher demand for API and thereby drive the growth of the overall market. The Asia-Pacific market for duloxetine API is considered to be growing significantly due to the rising healthcare spending and a growing number of contract manufacturing organizations (CMOs). In this region, Japan accounted for a market share of 13.7% in 2017. Moreover, the Middle East and Africa accounted for the least share of the market. The low market share is due to the limited number of companies manufacturing duloxetine API.
Key Findings of the Study:
- Global duloxetine API market is projected to reach USD 3,985.0 million by 2023 with 3.52% CAGR during the review period of 2018 to 2023.
- Americas accounted for the largest share in the region due to the rapidly growing prevalence of anxiety and depression.
- Some of the players operating in the duloxetine API market include Lupin, Teva Pharmaceutical Limited, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, Zydus Cadila, among others.
This research report provides insights, on various levels of analysis such as industry analysis, market share analysis, leading market players, and their profiles. This report also helps in studying the target segments by providing views on emerging and high-growth segments and market conclusion. Together the market data comprises and discusses basic assessments on the competitive scenarios and strategies of the global duloxetine API market, including the high-growth regions and their political, economic, and technological environments. Furthermore, the project report also provides views over historical market values as well as, pricing and cost analysis of the same.
Get access to full summary @ https://www.marketresearchfuture.com/reports/duloxetine-api-market-7707
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
NOTE : Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.
No comments:
Post a Comment